Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis

  1. Zeyad D Nassar
  2. Chui Yan Mah
  3. Jonas Dehairs
  4. Ingrid JG Burvenich
  5. Swati Irani
  6. Margaret M Centenera
  7. Madison Helm
  8. Raj K Shrestha
  9. Max Moldovan
  10. Anthony S Don
  11. Jeff Holst
  12. Andrew M Scott
  13. Lisa G Horvath
  14. David J Lynn
  15. Luke A Selth
  16. Andrew J Hoy
  17. Johannes V Swinnen
  18. Lisa M Butler  Is a corresponding author
  1. University of Adelaide, Australia
  2. KU Leuven, Belgium
  3. Olivia Newton-John Cancer Research Institute, Australia
  4. South Australian Health and Medical Research Institute, Australia
  5. University of Sydney, Australia
  6. University of New South Wales, Australia
  7. Chris O'Brien Lifehouse, Australia

Abstract

Fatty acid β-oxidation (FAO) is the main bioenergetic pathway in human prostate cancer (PCa) and a promising novel therapeutic vulnerability. Here we demonstrate therapeutic efficacy of targeting FAO in clinical prostate tumors cultured ex vivo, and identify DECR1, encoding the rate-limiting enzyme for oxidation of polyunsaturated fatty acids (PUFAs), as robustly overexpressed in PCa tissues and associated with shorter relapse-free survival. DECR1 is a negatively-regulated androgen receptor (AR) target gene and, therefore, may promote PCa cell survival and resistance to AR targeting therapeutics. DECR1 knockdown selectively inhibited β-oxidation of PUFAs, inhibited proliferation and migration of PCa cells, including treatment resistant lines, and suppressed tumor cell proliferation and metastasis in mouse xenograft models. Mechanistically, targeting of DECR1 caused cellular accumulation of PUFAs, enhanced mitochondrial oxidative stress and lipid peroxidation, and induced ferroptosis. These findings implicate PUFA oxidation via DECR1 as an unexplored facet of FAO that promotes survival of PCa cells.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

The following previously published data sets were used

Article and author information

Author details

  1. Zeyad D Nassar

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7779-2697
  2. Chui Yan Mah

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-8820-4037
  3. Jonas Dehairs

    Oncology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  4. Ingrid JG Burvenich

    Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  5. Swati Irani

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  6. Margaret M Centenera

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  7. Madison Helm

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  8. Raj K Shrestha

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  9. Max Moldovan

    Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  10. Anthony S Don

    Charles Perkins Centre, University of Sydney, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  11. Jeff Holst

    School of Medical Sciences, University of New South Wales, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  12. Andrew M Scott

    Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Australia
    Competing interests
    The authors declare that no competing interests exist.
  13. Lisa G Horvath

    Oncology, Chris O'Brien Lifehouse, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  14. David J Lynn

    Precision Medicine, South Australian Health and Medical Research Institute, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  15. Luke A Selth

    Medicine, University of Adelaide, Adelaide, Australia
    Competing interests
    The authors declare that no competing interests exist.
  16. Andrew J Hoy

    Charles Perkins Centre, University of Sydney, Sydney, Australia
    Competing interests
    The authors declare that no competing interests exist.
  17. Johannes V Swinnen

    Oncology, KU Leuven, Leuven, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  18. Lisa M Butler

    Medicine, University of Adelaide, Adelaide, Australia
    For correspondence
    lisa.butler@adelaide.edu.au
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-2698-3220

Funding

National Health and Medical Research Council (Early Career Fellowship,1138648)

  • Zeyad D Nassar

KU Leuven (Project Grants C16/15/073 and C32/17/052)

  • Johannes V Swinnen

Australian Research Council (Future Fellowship,FT130101004)

  • Lisa M Butler

Cancer Council South Australia (Beat Cancer Fellowship,PRF1117)

  • Lisa M Butler

Movember Foundation (Revolutionary Team Award,MRTA3)

  • Lisa M Butler

National Health and Medical Research Council (Project Grant,1121057)

  • Luke A Selth

National Health and Medical Research Council (Project Grant,1100626)

  • Anthony S Don

National Health and Medical Research Council (Fellowship,1084178)

  • Andrew M Scott

Prostate Cancer Foundation of Australia (Young Investigator Award,YI 1417)

  • Zeyad D Nassar

Cure Cancer Australia Foundation (Project Grant,1164798)

  • Zeyad D Nassar

EMBL Australia (Group Leader Award)

  • David J Lynn

University of Sydney (Robinson Fellowship)

  • Andrew J Hoy

Fonds Wetenschappelijk Onderzoek (Project Grants G.0841.15 and G.0C22.19N)

  • Johannes V Swinnen

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Nima Sharifi, Cleveland Clinic, United States

Ethics

Animal experimentation: Animal studies were approved by the Austin Health Animal Ethics Committee (approval number A2015/05311), Heidelberg, Australia, and the University of Adelaide Animal Ethics Committee (approval number M-2019-037), and were carried out in accordance with the recommendations of the National Health and Medical Research Council of Australia.

Human subjects: Fresh and archival prostate tissue specimens were collected from men undergoing robotic radical prostatectomy at St. Andrew's Hospital (Adelaide, South Australia) with written informed consent through the Australian Prostate Cancer BioResource. Ethical Approval was provided by the Human Research Ethics Committees of the University of Adelaide (H-2012-016) and St Andrew's Hospital.

Version history

  1. Received: December 4, 2019
  2. Accepted: July 16, 2020
  3. Accepted Manuscript published: July 20, 2020 (version 1)
  4. Version of Record published: July 28, 2020 (version 2)

Copyright

© 2020, Nassar et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 4,029
    Page views
  • 640
    Downloads
  • 82
    Citations

Article citation count generated by polling the highest count across the following sources: Scopus, Crossref, PubMed Central.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Zeyad D Nassar
  2. Chui Yan Mah
  3. Jonas Dehairs
  4. Ingrid JG Burvenich
  5. Swati Irani
  6. Margaret M Centenera
  7. Madison Helm
  8. Raj K Shrestha
  9. Max Moldovan
  10. Anthony S Don
  11. Jeff Holst
  12. Andrew M Scott
  13. Lisa G Horvath
  14. David J Lynn
  15. Luke A Selth
  16. Andrew J Hoy
  17. Johannes V Swinnen
  18. Lisa M Butler
(2020)
Human DECR1 is an androgen-repressed survival factor that regulates PUFA oxidation to protect prostate tumor cells from ferroptosis
eLife 9:e54166.
https://doi.org/10.7554/eLife.54166

Share this article

https://doi.org/10.7554/eLife.54166

Further reading

    1. Cancer Biology
    2. Computational and Systems Biology
    Bingrui Li, Fernanda G Kugeratski, Raghu Kalluri
    Research Article

    Non-invasive early cancer diagnosis remains challenging due to the low sensitivity and specificity of current diagnostic approaches. Exosomes are membrane-bound nanovesicles secreted by all cells that contain DNA, RNA, and proteins that are representative of the parent cells. This property, along with the abundance of exosomes in biological fluids makes them compelling candidates as biomarkers. However, a rapid and flexible exosome-based diagnostic method to distinguish human cancers across cancer types in diverse biological fluids is yet to be defined. Here, we describe a novel machine learning-based computational method to distinguish cancers using a panel of proteins associated with exosomes. Employing datasets of exosome proteins from human cell lines, tissue, plasma, serum, and urine samples from a variety of cancers, we identify Clathrin Heavy Chain (CLTC), Ezrin, (EZR), Talin-1 (TLN1), Adenylyl cyclase-associated protein 1 (CAP1), and Moesin (MSN) as highly abundant universal biomarkers for exosomes and define three panels of pan-cancer exosome proteins that distinguish cancer exosomes from other exosomes and aid in classifying cancer subtypes employing random forest models. All the models using proteins from plasma, serum, or urine-derived exosomes yield AUROC scores higher than 0.91 and demonstrate superior performance compared to Support Vector Machine, K Nearest Neighbor Classifier and Gaussian Naive Bayes. This study provides a reliable protein biomarker signature associated with cancer exosomes with scalable machine learning capability for a sensitive and specific non-invasive method of cancer diagnosis.

    1. Cancer Biology
    Carolyn M Jablonowski, Waise Quarni ... Jun Yang
    Research Article

    Dysregulated pre-mRNA splicing and metabolism are two hallmarks of MYC-driven cancers. Pharmacological inhibition of both processes has been extensively investigated as potential therapeutic avenues in preclinical and clinical studies. However, how pre-mRNA splicing and metabolism are orchestrated in response to oncogenic stress and therapies is poorly understood. Here, we demonstrate that jumonji domain containing 6, arginine demethylase, and lysine hydroxylase, JMJD6, acts as a hub connecting splicing and metabolism in MYC-driven human neuroblastoma. JMJD6 cooperates with MYC in cellular transformation of murine neural crest cells by physically interacting with RNA binding proteins involved in pre-mRNA splicing and protein homeostasis. Notably, JMJD6 controls the alternative splicing of two isoforms of glutaminase (GLS), namely kidney-type glutaminase (KGA) and glutaminase C (GAC), which are rate-limiting enzymes of glutaminolysis in the central carbon metabolism in neuroblastoma. Further, we show that JMJD6 is correlated with the anti-cancer activity of indisulam, a ‘molecular glue’ that degrades splicing factor RBM39, which complexes with JMJD6. The indisulam-mediated cancer cell killing is at least partly dependent on the glutamine-related metabolic pathway mediated by JMJD6. Our findings reveal a cancer-promoting metabolic program is associated with alternative pre-mRNA splicing through JMJD6, providing a rationale to target JMJD6 as a therapeutic avenue for treating MYC-driven cancers.